Sign in Subscribe
Western Hemisphere

BrainChild Bio Raises US$116 Million to Test CAR T in Childhood Brain Cancer

The Editor

The Editor

— 5 min read
Share
BraindChild CEO Steven Brugger and Founder/CSO Michael Jensen
BraindChild CEO Steven Brugger and Founder/CSO Michael Jensen

BrainChild Bio, a clinical-stage biotechnology company with offices in Seattle and Cambridge, Massachusetts, said on September 8, 2026 that it had closed a US$116 million Series A. The round was led by an undisclosed private family fund and foundation, with participation from Seattle Children's, an initial investor, and new investor WRF Capital. The company is run by Chief Executive Officer Steven Brugger and was founded in December 2023 by Michael Jensen, MD, who serves as Chief Scientific Officer, around an exclusive license to cell therapy technology developed at Seattle Children's.

The proceeds fund the pivotal Phase 2 ILLUMINATE study of BCB-276, an autologous CAR T cell therapy targeting B7-H3, a protein expressed broadly in diffuse intrinsic pontine glioma. DIPG is a brainstem tumor diagnosed in roughly 300 US children a year, mostly between ages 5 and 10, and it is effectively always fatal: standard care is palliative radiation and median survival runs about 11 months. Rather than infusing cells into the bloodstream, BrainChild delivers BCB-276 directly into cerebrospinal fluid through an implanted reservoir and catheter, dosing about every two weeks for up to 15 doses across seven to eight months. ILLUMINATE is an open-label, single-arm registrational trial enrolling 75 newly diagnosed patients after radiation across six pediatric neuro-oncology centers, with overall survival as the primary endpoint, a design the company says is aligned with the FDA for a future biologics license application. Topline data is expected in 2028. BCB-276 carries FDA Fast Track designation. A second candidate, BCB-214, targets B7-H3, EGFR and IL13Ra2 simultaneously and is moving toward first clinical testing in glioblastoma.

Market Context

The round is large for a rare pediatric indication, and the reason sits in the Phase 1 data. In the BrainChild-03 study, 21 DIPG patients received 253 intracerebroventricular doses, and median overall survival from diagnosis reached 19.8 months against the roughly 11-month baseline. Three patients were alive at 44.6, 45.6 and 52.5 months from diagnosis. In a disease where five decades of trials produced nothing that moved the survival curve, a doubling in a 21-patient study is the kind of signal that pulls in a nine-figure check.

The commercial comparison is Jazz Pharmaceuticals' Modeyso, which won accelerated FDA approval in August 2025 as the first treatment for recurrent H3 K27M-mutant diffuse midline glioma, on a 22% overall response rate in a population of roughly 2,000 US patients a year. Modeyso posted US$89.6 million in sales in the first half of 2026, which establishes that a small, fatal CNS indication can support real revenue. BrainChild is aiming at the earlier line Modeyso does not cover, newly diagnosed disease right after radiation, and at a much narrower patient count. The economics also improved on the policy side: Congress revived the rare pediatric disease priority review voucher program on February 3, 2026, running through September 2029, after it lapsed in December 2024. Vouchers have sold for as much as US$160 million, which for a company with 300 eligible patients a year is a material part of the return case. Roughly three dozen DIPG trials are currently recruiting, so the competitive field is crowded even if the approved-therapy field is not.

What Stands Out

"In the 50 years of clinical trials for DIPG, no drug had ever changed the 11-month overall survival mark." — Michael Jensen, MD, Founder and Chief Scientific Officer, BrainChild Bio

Regional Relevance

For the United States, this is a test of whether CAR T can work outside blood cancers. Six CAR T products are approved domestically and all treat hematologic malignancies, because solid tumors present barriers that liquid tumors do not: heterogeneous antigen expression, immunosuppressive microenvironments and, in the brain, a delivery problem that intravenous infusion does not solve. BrainChild's answer is locoregional dosing straight into the cerebrospinal fluid, repeated over months rather than given once. If ILLUMINATE reads out positive, the read-through extends well past DIPG to the far larger adult glioblastoma population, which is where BCB-214 is pointed. It is also a test of regulatory flexibility, since the trial asks the FDA to accept a single-arm overall survival study in place of a randomized comparison, on the argument that no control arm is ethically or practically available.

Washington State is the second layer. Seattle Children's is not just the licensor here but an equity holder, and WRF Capital is the investment arm of the Washington Research Foundation, which recycles returns from state university research into local companies. That combination is how the region has commercialized cell therapy since the Fred Hutchinson Cancer Center work that produced Juno Therapeutics, and it gives the state an unusual position: hospital, funder and spinout in the same ecosystem. The dual footprint in Cambridge reflects the practical reality that clinical and regulatory talent for a registrational program still concentrates in Massachusetts, so the science stays in Seattle while the development organization sits on the East Coast.

For pediatric oncology more broadly, the round lands in a venture market that has turned selective. Investor capital in biopharma is concentrating in clinical-stage assets with human data rather than platforms with promises, and a family foundation leading a US$116 million round in a 300-patient disease is a specific version of that shift: mission-driven capital taking on the risk that a generalist crossover fund would price out.

The Other Side

How much can a 21-patient single-arm study really tell you? Median survival of 19.8 months versus an 11-month benchmark is striking, but the comparison is against historical controls, not a randomized arm, and the patients who did best were the nine who started therapy soon after radiation, a group that may have been healthier to begin with. Selection effects have flattered early oncology data before. ILLUMINATE's 75 patients will be the first real test, and the answer does not arrive until 2028.

Is the delivery method scalable? BCB-276 requires an implanted reservoir, up to 15 separate dosing visits over seven to eight months, and autologous manufacturing for each child. That is a heavy protocol for families often traveling to one of six centers, and a demanding one commercially. Approved autologous CAR T products have struggled with manufacturing turnaround and site capacity in far larger indications; doing it repeatedly per patient raises the cost of goods and narrows the number of hospitals that can deliver it.

Does the financing model hold if the data is merely good? An undisclosed family fund and a hospital carry conviction that generalist investors have not yet shown for CNS cell therapy. A clean win pulls in crossover money and a plausible acquirer. An ambiguous result, in a disease with no approved frontline therapy and a priority review voucher on the table, leaves BrainChild dependent on the same narrow syndicate for a much longer stretch than a typical Series A implies.

Sources & Transparency

Read more